Abstract OT3-02-10: Nordic trip, a randomized phase 3 study in early triple negative breast cancer
Niklas Loman(Lund University), Henrik Lindman(Uppsala University), Johan Ahlgren(Uppsala University), B. Linderholm(Reykjavík University), Heikki Joensuu(Orion Corporation (Finland)), OT Johannsson(Reykjavík University), Jürgen Geisler(Oslo University Hospital), P-O Bendahl(Reykjavík University), Bent Ejlertsen
Cited by 3
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
|New England Journal of Medicine|2006|1.4k